Immutep Limited (IMMP)
| Market Cap | 169.70M |
| Revenue (ttm) | 4.36M |
| Net Income (ttm) | -24.54M |
| Shares Out | 89.31M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,261 |
| Open | 1.86 |
| Previous Close | 1.86 |
| Day's Range | 1.81 - 1.91 |
| 52-Week Range | 1.50 - 3.90 |
| Beta | 1.99 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+347.37%) |
| Earnings Date | Oct 30, 2023 |
About IMMP
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 t... [Read more]
Financial Performance
In 2022, Immutep's revenue was 6.76 million, an increase of 70.31% compared to the previous year's 3.97 million. Losses were -32.21 million, 7.72% more than in 2021.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IMMP stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 347.37% from the latest price.
News
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved
Immutep to Participate in September Investor Conferences
SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapi...
Immutep Receives Positive Scientific Advice from European Medicines Agency
Media Release SYDNEY, AUSTRALIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
Immutep Quarterly Activities Report Q4 FY23
Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC...
Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023
Media Release Mini O ral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus KEYTRUDA® ( pembrolizumab) Two additional posters on inv...
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
Immutep Completes A$80 Million Capital Raise
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer an...
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer an...
Immutep to Participate at the Jefferies Healthcare Conference
SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapie...
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-...
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an i...
Immutep Selects Charles River Laboratories for IMP761's GLP Toxicology Study
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep's preclinical toxicology study evaluating the safety and toxicity of IMP761 Forms a key step prior to first-in-...
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Deep, durable resp...
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Media Release SYDNEY, AUSTRALIA, May 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 i...
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
Media Release Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacy...
Immutep's Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI...
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
Media Release SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 i...
Immutep to Participate in the JMP Securities Life Sciences Conference
Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 i...
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
Media Release Webinar to take place on Tuesday, May 9, 2023, at 11:30 AM ET SYDNEY, AUSTRALIA, May 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology...
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO® in metastatic urot...
Immutep Quarterly Activities Report
Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancer Positi...
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
Media Release Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) --...
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
Media Release SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer ...
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosis First time efti will be studied in neoadjuvant, non-metastatic cancer setting Novel tri...